Each tablet contains 120 mg of Dihydroartemisinin and 960 mg of Piperaquine Phosphate, along with excipients including Brilliant blue, Indigo carmine, and Titanium dioxide.
Treatment of uncomplicated Plasmodium falciparum malaria.
Orally with water on an empty stomach daily for 3 days. Dosage should be determined by a doctor based on the patient's weight.
Hypersensitivity to dihydroartemisinin, piperaquine phosphate, or any of the excipients. First trimester of pregnancy.
Caution with hepatic or renal impairment. Do not exceed the stated dosage.
Nausea, vomiting, reversible reduction in reticulocyte counts (dihydroartemisinin), mild dizziness, vertigo, headache, nausea, vomiting, abdominal discomfort, reversible leucopenia, dyspnea, and palpitations (piperaquine phosphate).
Dihydroartemisinin: Rapid absorption, peak concentration within 1 hour, half-life ~4 hours, widely distributed, ~80% excreted within 24 hours.Piperaquine Phosphate: 80-90% absorbed within 24 hours, widely distributed, slow elimination, half-life ~9.4 days, excreted in bile.
CYP3A4 inhibitors, CYP2C19 inhibitors, rifampicin, carbamazepine, phenytoin, and phenobarbital.
Symptomatic and supportive therapy, ECG monitoring.
Not recommended during pregnancy, especially the first trimester. Women taking P-Alaxin TS should not breastfeed.
Dry place below 30°C, protected from light, out of reach of children.
Blister packs of 3 tablets.
Dihydroartemisinin: Interferes with P. falciparum trophozoite membrane structures, disrupts protein and nucleic acid synthesis.Piperaquine Phosphate: Interferes with the trophozoite food vacuole membrane function.